Capnomed

Executive Summary

Capnomed is a privately held Chinese medical device company specializing in non-invasive capnography and gas analysis for respiratory and metabolic monitoring. Founded in 2015 and headquartered in Shenzhen, the company has achieved commercial stage with products targeting chronic respiratory conditions such as COPD and sleep apnea, as well as metabolic disorders. Capnomed’s core technology provides real-time, accurate data for clinical and home-care settings, addressing the growing demand for remote patient monitoring and personalized medicine. With a workforce of 50-200 employees, the company is well-positioned to capitalize on the expanding Chinese healthcare market and global shift toward non-invasive diagnostics. While specific financials and pipeline details are limited, Capnomed’s focus on innovative monitoring solutions aligns with key trends in digital health and chronic disease management. The company’s ability to secure regulatory approvals and forge strategic partnerships will be critical for scaling its commercial footprint and driving revenue growth.

Upcoming Catalysts (preview)

• H2 2026NMPA approval for next-generation capnography device with enhanced home-use features75% success
• H1 2026Strategic distribution partnership with a major Chinese hospital chain or home healthcare provider65% success
• Q3 2026Launch of a new metabolic monitoring add-on module for existing capnography platform60% success